Pfizer Initiates Study to Evaluate its Pneumococcal Vaccine with Booster dose of its COVID-19 Vaccine
Shots:
- The first enrolled patient has received their immunizations as part of a new study in adults ≥65yrs. evaluating the coadministration of 20vPnC with a booster dose of the Pfizer-BioNTech’s COVID-19 vaccine
- The trial will include ~600 adults who will be recruited from the P-III COVID-19 vaccine trial and will have received their second dose of the vaccine at least 6mos. before entering the coadministration study
- The primary objective in the trial is to describe safety when both vaccines are co-administered- with follow up 6mos. after vaccination. The secondary objective is to describe immune responses produced by each of the vaccines
Ref: Pfizer | Image: Business Wire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com